NASDAQ:TSRX - Trius Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Trius Therapeutics (NASDAQ:TSRX)

Trius Therapeutics logoTrius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibiotics for life threatening infections. The Company is developing torezolid phosphate, an intraveneous (IV) and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections (ABSSSI), and subsequently for other indications. In addition, the Company is developing antibiotics for gram-negative infections using its discovery platform under two contracts: one funded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH) and the other funded by the Defense Threat Reduction Agency (DTRA), a part of the Department of Defense. In September 2013, Cubist Pharmaceuticals Inc announced that it has completed the acquisition of Trius Therapeutics Inc.

Receive TSRX News and Ratings via Email

Sign-up to receive the latest news and ratings for TSRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Trius Therapeutics (NASDAQ:TSRX) Frequently Asked Questions

What is Trius Therapeutics' stock symbol?

Trius Therapeutics trades on the NASDAQ under the ticker symbol "TSRX."

Has Trius Therapeutics been receiving favorable news coverage?

News stories about TSRX stock have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Trius Therapeutics earned a news impact score of 0.21 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.65 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Trius Therapeutics?

Shares of TSRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Trius Therapeutics?

Trius Therapeutics' mailing address is 65 Hayden Ave, LEXINGTON, MA 02421-7994, United States. The biopharmaceutical company can be reached via phone at +1-781-8608660.

MarketBeat Community Rating for Trius Therapeutics (TSRX)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  160
MarketBeat's community ratings are surveys of what our community members think about Trius Therapeutics and other stocks. Vote "Outperform" if you believe TSRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Trius Therapeutics (NASDAQ:TSRX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/25/2016 forward)


Trius Therapeutics (NASDAQ:TSRX) Earnings History and Estimates Chart

Earnings by Quarter for Trius Therapeutics (NASDAQ:TSRX)

Trius Therapeutics (NASDAQ TSRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2013Q212($0.33)($0.41)$3.71 million$1.30 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.33)($0.34)$6.31 million$1.73 millionViewN/AView Earnings Details
3/12/2013Q4 2012($0.44)($0.40)ViewN/AView Earnings Details
11/5/2012Q3 2012($0.42)($0.46)ViewN/AView Earnings Details
8/6/2012Q2 2012($0.38)($0.37)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.31)($0.22)ViewN/AView Earnings Details
3/13/2012Q4 2011($0.49)($0.40)ViewN/AView Earnings Details
11/10/2011Q3 2011($0.35)$0.41ViewN/AView Earnings Details
8/11/2011Q2 2011($0.40)($0.40)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.39)($0.43)ViewN/AView Earnings Details
3/23/2011Q4 2010($0.46)($0.37)ViewN/AView Earnings Details
11/11/2010Q3 2010($0.32)($0.57)ViewN/AView Earnings Details
8/19/2010Q2 2010($2.69)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Trius Therapeutics (NASDAQ:TSRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Trius Therapeutics (NASDAQ TSRX) Insider Trading and Institutional Ownership History

Insider Trading History for Trius Therapeutics (NASDAQ:TSRX)

Trius Therapeutics (NASDAQ TSRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/22/2013John FinnInsiderSell1,000$12.10$12,100.00View SEC Filing  
7/15/2013John FinnInsiderSell3,500$10.55$36,925.00View SEC Filing  
7/12/2013John FinnInsiderSell6,500$9.81$63,765.00View SEC Filing  
7/11/2013Michael MorneauCAOSell20,000$9.75$195,000.00View SEC Filing  
7/1/2013Philippe ProkocimerInsiderSell2,000$8.14$16,280.00View SEC Filing  
6/12/2013John FinnInsiderSell3,000$9.08$27,240.00View SEC Filing  
6/11/2013John FinnInsiderSell1,000$8.94$8,940.00View SEC Filing  
6/4/2013Ken BartizalInsiderSell2,000$7.90$15,800.00View SEC Filing  
6/3/2013Philippe ProkocimerInsiderSell2,000$7.75$15,500.00View SEC Filing  
5/24/2013Philippe ProkocimerInsiderSell12,000$7.93$95,160.00View SEC Filing  
5/14/2013Ken BartizalInsiderSell12,000$7.85$94,200.00View SEC Filing  
5/14/2013Michael MorneauCAOSell20,000$7.75$155,000.00View SEC Filing  
5/13/2013Philippe ProkocimerInsiderSell12,000$7.65$91,800.00View SEC Filing  
5/10/2013John FinnInsiderSell3,000$7.48$22,440.00View SEC Filing  
(Data available from 1/1/2013 forward)


Trius Therapeutics (NASDAQ TSRX) News Headlines

Trius Therapeutics (TSRX) & Vericel (VCEL) Head to Head ContrastTrius Therapeutics (TSRX) & Vericel (VCEL) Head to Head Contrast - January 30 at 9:39 AM
Constellation Pharmaceuticals Completes Management Team with Key Leadership AppointmentsConstellation Pharmaceuticals Completes Management Team with Key Leadership Appointments - October 25 at 1:43 AM
Contrasting Trius Therapeutics (TSRX) & Jazz Pharmaceuticals PLC (JAZZ)Contrasting Trius Therapeutics (TSRX) & Jazz Pharmaceuticals PLC (JAZZ) - October 10 at 2:16 PM

SEC Filings

Trius Therapeutics (NASDAQ:TSRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Trius Therapeutics (NASDAQ:TSRX) Income Statement, Balance Sheet and Cash Flow Statement


Trius Therapeutics (NASDAQ TSRX) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.